These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36672123)

  • 1. Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression.
    Gałuszko-Węgielnik M; Chmielewska Z; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ
    Brain Sci; 2023 Jan; 13(1):. PubMed ID: 36672123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder.
    Gałuszko-Wȩgielnik M; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ; Pastuszak M
    Front Neurosci; 2023; 17():1214972. PubMed ID: 37496742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
    Le TT; Di Vincenzo JD; Teopiz KM; Lee Y; Cha DS; Lui LMW; Rodrigues NB; Ho RC; Cao B; Lin K; Nasri F; Gill H; Lipsitz O; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
    Psychiatry Res; 2021 Dec; 306():114231. PubMed ID: 34798487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy.
    Alario AA; Niciu MJ
    Chronic Stress (Thousand Oaks); 2022; 6():24705470221128017. PubMed ID: 36276228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression.
    Souza-Marques B; Telles M; Leal GC; Faria-Guimarães D; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Souza L; Lins-Silva D; Mello RP; Guerreiro-Costa L; Bandeira ID; Lacerda ALT; Sampaio AS; Quarantini LC
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):408-412. PubMed ID: 35727083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Intranasal esketamine for severe major depressive disorder with psychotic features.
    Carter M; Solsrud K; Mischel N
    Front Psychiatry; 2022; 13():937996. PubMed ID: 35958651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
    Kim S; Rush BS; Rice TR
    Eur Child Adolesc Psychiatry; 2021 Oct; 30(10):1485-1501. PubMed ID: 32385697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine - Undrawn Lines between Medical and Recreational Use - Implications for Clinical Practice.
    Jonovska S; Sugnet T; Šendula-Jengić V
    Psychiatr Danub; 2021; 33(Suppl 4):1113-1117. PubMed ID: 35354177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine for depression clinical issues.
    Iqbal SZ; Mathew SJ
    Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of ketamine and esketamine in treatment of depression.
    Nikayin S; Murphy E; Krystal JH; Wilkinson ST
    Expert Opin Drug Saf; 2022 Jun; 21(6):777-787. PubMed ID: 35416105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.
    Correia-Melo FS; Leal GC; Carvalho MS; Jesus-Nunes AP; Ferreira CBN; Vieira F; Magnavita G; Vale LAS; Mello RP; Nakahira C; Argolo FC; Cardoso T; Souza CDS; Fontes ATC; Ferreira MB; Araújo-de-Freitas L; Tuena MA; Echegaray MVF; Cavalcanti DE; Lucchese AC; Bandeira ID; Telles M; Lima CS; Sampaio AS; Silva SS; Marback RF; Del-Porto JA; Abreu JN; Sarin LM; Paixão CS; Carvalho LP; Machado PRL; Turecki G; Lacerda ALT; Quarantini LC
    Medicine (Baltimore); 2018 Sep; 97(38):e12414. PubMed ID: 30235716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid antidepressant effect of S-ketamine in schizophrenia.
    Bartova L; Papageorgiou K; Milenkovic I; Dold M; Weidenauer A; Willeit M; Winkler D; Kasper S
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):980-982. PubMed ID: 30041987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.